Skip to main content
Fuan Pharmaceutical （Group）co.,Ltd logo

Fuan Pharmaceutical （Group）co.,Ltd — Investor Relations & Filings

Ticker · 300194 ISIN · CNE1000011G4 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,014 across all filing types
Latest filing 2017-11-22 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300194

About Fuan Pharmaceutical （Group）co.,Ltd

https://www.fapharm.com

Fuan Pharmaceutical (Group) Co., Ltd. is an integrated pharmaceutical enterprise specializing in the research, development, production, and distribution of a wide range of chemical drugs. The company operates across the entire value chain, encompassing pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and finished dosage forms. Its product portfolio primarily focuses on anti-infectives, particularly cephalosporins and penicillins, as well as treatments for cardiovascular diseases, oncology, and respiratory conditions. Fuan Pharmaceutical maintains large-scale manufacturing facilities and emphasizes technological innovation to support its diverse pipeline of generic and specialized medications. The group serves both domestic and international markets, providing essential healthcare solutions through its network of subsidiaries and specialized production bases.

Recent filings

Filing Released Lang Actions
关于收到药品审批意见通知件的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from a company regarding the receipt of a regulatory approval notice from the National Medical Products Administration (国家食品药品监督管理总局) about a drug registration application being rejected. It contains no financial data, no report or presentation, and is not a meeting or voting related document. It is a regulatory announcement about a drug approval decision, which fits best under Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories.
2017-11-22 Chinese
关于股东股份减持计划实施进展情况的公告
Major Shareholding Notification Classification · 100% confidence The document is an announcement regarding the progress of a shareholder's plan to reduce their shareholding in the company. It details the number of shares reduced, the methods of reduction, dates, and compliance with relevant regulations. It does not contain financial statements or performance data, nor is it a report or presentation. It is a regulatory announcement about a major shareholder's transaction activity, specifically a reduction in shareholding. This fits the category of Major Shareholding Notification (MRQ). The document length is short and focused on shareholding changes, confirming MRQ classification.
2017-11-19 Chinese
关于子公司收到药品GMP证书的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (719 characters) from a company about its subsidiary receiving a GMP certificate for pharmaceutical production. It contains no financial data, no mention of financial results, no regulatory filings related to financial performance, no voting results, no management changes, no capital updates, and no legal proceedings. It is an operational update about certification received, which is a regulatory announcement but not a financial report or other specific filing type. Given the content and length, it fits best under Regulatory Filings (RNS) as a general announcement that does not fit other categories.
2017-11-09 Chinese
关于收到药品补充申请批件的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement from a company about receiving an approval notice from a regulatory authority (国家食品药品监督管理总局) for a drug supplement application. It does not contain financial data, management discussion, or detailed report content. The length is only 646 characters, indicating it is a brief announcement rather than a full report. It is not a financial report, earnings release, or management report. It is a regulatory announcement about product approval, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other categories.
2017-11-07 Chinese
关于公司部分高级管理人员股份减持计划的预披露公告
Director's Dealing Classification · 95% confidence The document is a pre-disclosure announcement regarding a share reduction plan by certain senior management personnel of the company. It details the shareholders involved, their positions, shareholdings, proposed reduction quantities, methods, and timing. The document is an announcement of a planned transaction by insiders (senior management) to reduce their shareholdings. It does not contain financial statements, audit information, or detailed financial results. It is not a report or a regulatory filing about financial performance but a notification about insider share transactions. Therefore, it fits the category of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives (insider trades). The document length is 1889 characters, consistent with an announcement rather than a full report.
2017-11-03 Chinese
关于公司在研产品进展的提示性公告
Regulatory Filings Classification · 95% confidence The document is a short announcement from the company about progress in regulatory approval for a product under development. It does not contain financial data, detailed reports, or meeting materials. It is a typical regulatory update or general announcement about product development status. The document length is only 546 characters, indicating it is a brief notice rather than a full report. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a voting result, board change, or legal proceeding. The best fit is Regulatory Filings (RNS), which covers general regulatory announcements and miscellaneous filings that do not fit other categories.
2017-10-31 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.